American Diabetes Association. Management of dyslipidaemia in adults with diabetes. Diabetes Care 1999; 22(Suppl 1):S56-59.

Anderson KM, Odell PM, Wilson PWF et al. Cardiovascular disease risk profiles. Am Heart J 1990; 121:293-298.

Athyros VG, Papageorgiou AA, Mercouris BR et al. Treatment with atorvastatin to the National Cholesterol Educational Program Goal versus 'usual' care in secondary coronary heart disease prevention. Curr Med Res Opin 2002; 18:220-228.

Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992; 70:733-737.

Austin MA, King M-C, Vranizan KM et al. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82:495-506.

Barrett-Connor EL, Cohn BA, Wingard DL et al. Why is diabetes mellitus a stronger risk factor for fatal ischaemic heart disease in women than in men? The Rancho Benardo Study. JAMA 1991; 265:627-631.

Barter P. CETP and atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20:2029-2031.

Bhatnagar D, Morgan J, Siddiq S et al. Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ 2000; 321:1497-1500.

Borch-Johnsen K, Kreiner S. Proteinuria: value as a predictor of cardiovascular mortality in insulin dependent diabetes mellitus. BMJ 1987; 294:1651-1654.

British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society and endorsed by the British Diabetic Association. Joint British recommendations in prevention of coronary heart disease in clinical practice. Heart 1998; 80(Suppl 2):S1-S29.

British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. BMJ 2000; 320:705-708.

Brunzell JD. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: The Metabolic and Molecular Bases of Inherited Disease. 7th Edition. Edited by CR Scriver, AL Beaudet, WS Sly and D Valle. McGraw-Hill: New York, 1995;1913-1932.

Carlson LA. Fish eye disease: a new familial condition with massive corneal opacities and dyslipoproteinaemia. Eur J Clin Invest 1982; 12:41-53.

Chait A, Brazg RL, Tribble DL et al. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993; 94:350-356.

Craig WY, Neveux LM, Palomaki GE et al. Lipoprotein (a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998; 44:2301-2306.

Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of the AFCAPS/TexCAPS. JAMA 1998; 279:1615-1622.

Durrington PN. Diabetic dyslipidaemia. Baillieres Best Pract Res Clin Endocrinol Metab 1999; 13:265-278.

Durrington PN. Hyperlipidaemia: Diagnosis and Management. 2nd edition. London: Butterworth-Heinemann; 1995a (3rd edition to be published in 2002).

Durrington PN. Lipoprotein (a). Ballieres Clin Endocrinol Metab 1995b; 9:773-795.

Durrington PN. Rigorous detection and vigorous treatment of familial hypercholesterolaemia. Lancet 2001; 357:574-575.

Durrington PN. Triglycerides are more important in atherosclerosis than epidemiology has suggested. Atherosclerosis 1998; 141(Suppl 1):S57-S62.

Egger M, Davey Smith G, Pfluger D et al. Triglyceride as a risk factor for ischaemic heart disease in British men: effect of adjusting for measurement error. Atherosclerosis 1999; 143:275-284.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285:2486-2497.

Glomset JA, Assmann G, Gjone E et al. Lecithin: cholesterol acyltransferase deficiency and Fish eye disease. In: The Metabolic and Molecular Bases of Inherited Disease. 7th Edition. Edited by CR Scriver, AL Beaudet, WS Sly and D Valle. McGraw-Hill: New York, 1995;1933-1951.

Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: The Metabolic and Molecular Bases of Inherited Disease. 7th Edition. Edited by CR Scriver, AL Beaudet, WS Sly and D Valle. McGraw-Hill: New York, 1995;1981-2030.

Griffin BA, Freeman DJ, Tait GW et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994; 106:241-253.

Haffner SM, Stern MP, Hazuda HP et al. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary disease start ticking before the onset of clinical diabetes? JAMA 1990; 263:2893-2898.

Heaney AP, Sharer N, Rameh B et al. Prevention of recurrent pancreatitis in familial lipoprotein lipase deficiency with high dose antioxidant therapy. J Clin End Metab 1999; 84:1203-1205.

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.

Hebert PR, Gaziano JM, Chan KS et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278:313-321.

Herz J. Low-density lipoprotein receptor-related protein. In: Lipoproteins in Health and Disease. Edited by DJ Betteridge, DR Illingworth and J Shepherd. London: Arnold, 1999;333-359.

Hobbs HH, White AL. Lipoprotein (a): intrigues and insights. Curr Opin Lipidol 1999; 10:225-236.

Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3:213-219.

Jones AF, Walker J, Jewkes C et al. Comparative accuracy of cardiovascular risk prediction methods in primary care patients. Heart 2001; 85:37-43.

Kane JP, Havel RJ. Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In: The Metabolic and Molecular Bases of Inherited Disease. 7th Edition. Edited by CR Scriver, AL Beaudet, WS Sly and D Valle. McGraw-Hill: New York, 1995;1853-1885.

Lamarche B, Tchernof A, Moorjani S et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation 1997; 95:69-75.

Law MR, Wald NJ, Wu T et al. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ 1994; 308:363-366.

Mahley RW, Rall SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: The Metabolic and Molecular Bases of Inherited Disease. 7th Edition. Edited by CR Scriver, AL Beaudet, WS Sly and D Valle. McGraw-Hill: New York, 1995;1953-1980.

Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 1997; 17:3542-3556.

Pekkanen J, Linn S, Heiss G et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without pre-existing cardiovascular disease. N Engl J Med 1990; 322:1700-1707.

Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 2000; 321:1322-1325.

Reaven GM, Ida Chen Y-D, Jeppesen J et al. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 1993; 92:141-146.

Rifkind BM, Segal P. Lipid Research Clinics Program reference values of hyperlipidemia and hypolipidemia. JAMA 1983; 250:1869-1872.

Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341:410-418.

Schumaker V, Lambertas A. Lipoprotein metabolism: chylomicrons, very-low density lipoproteins and low density lipoproteins. In: Molecular Genetics of Coronary Artery Disease. Edited by AJ Lusis, JI Rotter and RS Sparkes. Basel: Karger, 1992;98-139.

Simons LA. Interrelations of lipids and lipoproteins with coronary artery disease mortality in 19 countries. Am J Cardiol 1986; 57:5G-10G.

Sweetnam PM, Bolton CH, Downs LG et al. Apolipoproteins A-I, A-II and B, lipoprotein (a) and the risk of ischaemic heart disease: the Caerphilly Study. Eur J Clin Invest 2000; 30:947-956.

The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000; 102:21-27.

Umans-Eckenhausen MAW, Defesche JC, Sijbrands EJG et al. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001; 357:165-168.

Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88:1785-1792.

Wood D, De Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140:199-270.